Polyrizon (PLRZ) Competitors $0.36 -0.01 (-1.96%) As of 04/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. GTBP, NKGN, FRTX, CDT, BCLI, SNGX, NCNA, NLSP, AEZS, and SPRBShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include GT Biopharma (GTBP), NKGen Biotech (NKGN), Fresh Tracks Therapeutics (FRTX), Conduit Pharmaceuticals (CDT), Brainstorm Cell Therapeutics (BCLI), Soligenix (SNGX), NuCana (NCNA), NLS Pharmaceutics (NLSP), Aeterna Zentaris (AEZS), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. GT Biopharma NKGen Biotech Fresh Tracks Therapeutics Conduit Pharmaceuticals Brainstorm Cell Therapeutics Soligenix NuCana NLS Pharmaceutics Aeterna Zentaris Spruce Biosciences Polyrizon (NASDAQ:PLRZ) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Which has preferable earnings and valuation, PLRZ or GTBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/AN/AN/AN/AGT BiopharmaN/AN/A-$7.60M-$7.00-0.32 Do analysts recommend PLRZ or GTBP? GT Biopharma has a consensus target price of $11.00, indicating a potential upside of 384.58%. Given GT Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe GT Biopharma is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media prefer PLRZ or GTBP? In the previous week, Polyrizon and Polyrizon both had 1 articles in the media. GT Biopharma's average media sentiment score of 1.00 beat Polyrizon's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Polyrizon Neutral GT Biopharma Positive Does the MarketBeat Community favor PLRZ or GTBP? GT Biopharma received 117 more outperform votes than Polyrizon when rated by MarketBeat users. CompanyUnderperformOutperformPolyrizonN/AN/AGT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% Is PLRZ or GTBP more profitable? Polyrizon's return on equity of 0.00% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A GT Biopharma N/A -257.47%-131.09% Do institutionals and insiders believe in PLRZ or GTBP? 8.1% of GT Biopharma shares are held by institutional investors. 10.9% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryGT Biopharma beats Polyrizon on 8 of the 10 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49M$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.34%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9497.72Price / CashN/A65.6738.3134.64Price / BookN/A5.936.453.98Net IncomeN/A$143.22M$3.22B$247.81M7 Day Performance-7.03%4.28%5.85%3.19%1 Month Performance-35.94%-13.11%-9.58%-7.70%1 Year PerformanceN/A-8.51%11.85%1.49% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$0.36-2.0%N/AN/A$1.49MN/A0.00N/AGap UpGTBPGT Biopharma3.4382 of 5 stars$2.25-5.1%$11.00+388.9%-37.8%$5.71MN/A-0.328Short Interest ↓Positive NewsGap DownNKGNNKGen BiotechN/A$0.13-3.2%N/A-88.5%$5.66M$80,000.00-0.02N/AGap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+3.9%$5.59M$10.06M-0.6620CDTConduit Pharmaceuticals0.221 of 5 stars$0.78-13.0%N/A-99.8%$5.20MN/A-0.023Gap UpHigh Trading VolumeBCLIBrainstorm Cell Therapeutics3.5993 of 5 stars$0.80+2.2%$30.00+3,673.6%-89.0%$5.19MN/A-0.1740Analyst ForecastSNGXSoligenix1.2993 of 5 stars$2.06+3.0%N/A-69.5%$5.17M$840,000.00-0.2720Short Interest ↓Positive NewsGap DownNCNANuCana2.6423 of 5 stars$0.91+4.3%$25.00+2,656.3%-77.2%$5.15MN/A-0.0930NLSPNLS PharmaceuticsN/A$1.43-4.7%N/A+1,000.2%$5.15MN/A0.006Short Interest ↓Positive NewsGap UpAEZSAeterna ZentarisN/A$2.84-2.4%N/A-63.7%$5.09M$2.37M-0.1920Analyst ForecastNews CoverageSPRBSpruce Biosciences2.7705 of 5 stars$0.12-6.8%$2.17+1,661.5%-83.1%$5.08M$7.10M-0.1320Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies GT Biopharma Alternatives NKGen Biotech Alternatives Fresh Tracks Therapeutics Alternatives Conduit Pharmaceuticals Alternatives Brainstorm Cell Therapeutics Alternatives Soligenix Alternatives NuCana Alternatives NLS Pharmaceutics Alternatives Aeterna Zentaris Alternatives Spruce Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
